دورية أكاديمية
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation.
العنوان: | Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. |
---|---|
المؤلفون: | Nang SC; Biomedicine Discovery Institute, Infection Program, Department of Microbiology, Monash University, Victoria, Australia., Lin YW; Biomedicine Discovery Institute, Infection Program, Department of Microbiology, Monash University, Victoria, Australia., Petrovic Fabijan A; Westmead Hospital, Western Sydney Local Health District, Westmead, New South Wales, Australia; Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Westmead, New South Wales, Australia; School of Medicine, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia., Chang RYK; Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; AcuraBio Pty Ltd, Darra, Queensland, Australia., Rao GG; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, North Carolina, USA., Iredell J; Westmead Hospital, Western Sydney Local Health District, Westmead, New South Wales, Australia; Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Westmead, New South Wales, Australia; School of Medicine, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia., Chan HK; Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia., Li J; Biomedicine Discovery Institute, Infection Program, Department of Microbiology, Monash University, Victoria, Australia. Electronic address: jian.li@monash.edu. |
المصدر: | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2023 Jun; Vol. 29 (6), pp. 702-709. Date of Electronic Publication: 2023 Feb 02. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9516420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-0691 (Electronic) Linking ISSN: 1198743X NLM ISO Abbreviation: Clin Microbiol Infect Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2015- : London : Elsevier Original Publication: Paris : Decker Europe, c1995- |
مواضيع طبية MeSH: | Phage Therapy* , Anti-Infective Agents*/pharmacology , Bacteriophages*, Humans ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacteria |
مستخلص: | Background: The increasing emergence of antimicrobial resistance worldwide has led to renewed interest in phage therapy. Unlike antibiotics, the lack of pharmacokinetics/pharmacodynamics (PK/PD) information represents a major challenge for phage therapy. As therapeutic phages are biological entities with the ability to self-replicate in the presence of susceptible bacteria, their PK/PD is far more complicated than that of antibiotics. Objectives: This narrative review examines the current literature on phage pharmacology and highlights major pharmacological challenges for phage therapy. Sources: Included articles were identified by searching PubMed and Google Scholar till June 2022. The search terms were 'bacteriophage', 'antimicrobial', 'pharmacokinetics' and 'pharmacodynamics'. Additional relevant references were obtained from articles retrieved from the primary search. Content: In this review, phage PK is first discussed, focusing on absorption, distribution, metabolism, and elimination. Key factors affecting phage antimicrobial activities are reviewed, including multiplicity of infection, passive and active phage therapy, and the involvement of the human immune system. Importantly, we emphasize the impact of phage self-replication on the PK/PD and the fundamental phage characteristics that are required for PK/PD modelling and clinical translation. Implications: Recent progress in phage pharmacology has shown that we are in a far better position now to treat infections with phage therapy than a century ago. However, phage therapy is still in its infancy when compared to antibiotics due to the scarce pharmacological knowledge (e.g. PK/PD). Optimization of phage PK/PD is key for translation of phage therapy in patients. (Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.) |
فهرسة مساهمة: | Keywords: Antimicrobial; Bacteriophage; Pharmacodynamics; Pharmacokinetics; Self-replication |
المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Anti-Infective Agents) |
تواريخ الأحداث: | Date Created: 20230203 Date Completed: 20230605 Latest Revision: 20230605 |
رمز التحديث: | 20231215 |
DOI: | 10.1016/j.cmi.2023.01.021 |
PMID: | 36736661 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1469-0691 |
---|---|
DOI: | 10.1016/j.cmi.2023.01.021 |